Episode 14. MRD in Multiple Myeloma
In this episode, we delve into MRD in myeloma with Dr. Luciano Costa and discuss the data for 3 key clinical implications: MRD as a prognostic biomarker, MRD as a tool for treatment modification, and MRD as a surrogate endpoint for drug approval.
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
1. Excellent paper on harmonization of performing and reporting MRD in multiple myeloma:
https://www.nature.com/articles/s41375-020-01012-4
2. Does CR really matter in the era of MRD? Landmark paper from the Spanish Group:
https://pubmed.ncbi.nlm.nih.gov/35560160/
3. Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple myeloma:
https://pubmed.ncbi.nlm.nih.gov/33284948/
4. MASTER Trial-The first trial testing MRD-adapted treatment strategy in multiple myeloma :
https://pubmed.ncbi.nlm.nih.gov/34898239/